Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase NA 1

Status

Completed 4Unknown 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 4Breast 1

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC) 2Severe Acute Respiratory Syndrome 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Neoadjuvant Therapy \High Risk Prostate Cancer 1COVID-19 1Breast Neoplasms 1Alopecia 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × proxalutamide × Clear all
NCT03899467 2024-02-12

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Suzhou Kintor Pharmaceutical Inc,

Phase 2 Completed
61 enrolled 12 charts
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT04446429 2021-12-10

Anti-Androgen Treatment for COVID-19

Applied Biology, Inc.

Phase NA Completed
268 enrolled 8 charts
Genitourinary

COVID-19, Alopecia, Prostatic Hyperplasia, Prostatic Neoplasms, Severe Acute Respiratory Syndrome

NCT05076851 2021-10-13

Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy(ADT)for High Risk Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
2 enrolled
Genitourinary

Neoadjuvant Therapy \High Risk Prostate Cancer

NCT04103853 2021-09-24

Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer

Suzhou Kintor Pharmaceutical Inc,

Phase 1 Completed
63 enrolled
Breast

Breast Neoplasms

NCT02826772 2020-03-17

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Suzhou Kintor Pharmaceutical Inc,

Phase 1 Completed
40 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡